Yes, Sir. I saw your post the other day and post from a couple other people on other boards with similar lines of thinking And I also had those conversations with people who are biotech investors, and also working industry and I agree with that- Something is going on.
There is a combination of PFE, GSK and ViiV And maybe they have some sort of agreement together or maybe it is just ViiV That is making the move.
But the appointment of Dr. LATA is certainly the first real card we have been dealt that shows us that there is a collaboration going on possibly licensing and partnership, and hopefully the goal of a buyout.
The global component is interesting, but I don’t want to go down the road that MGK2 Going down that says we are going to subvert the FDA by going into another country first. We have gone through hell with the FDA and Dr. Jay has resurrected that relationship and it would be incredibly foolish to not go through the FDA first.. The biggest market in medicine is the United States and that’s where we need to be focused and we have been told that we have a healthy promising relationship with the FDA so let’s keep going down that path
Sure, we can go overseas later and we can begin to build relationships of course but just because GSK is based out of London and has important relationships with the EMA does not mean that they don’t also have equally solid relationships with our FDA.
Doctor LATA is here for a reason and he certainly is in a position to keep a very close eye on the molecule and what CYDY does with it. He is something we have been missing for as long as I have known about this molecule, which is coming up on 11 years..
So what I have talked about tonight with my multiple posts As was pointed out byrodolfo, Is that it seems something is brewing and that something is with big Pharma.
We had MERCK with the Keytrufa Mouse studies at MD Anderson and we have been on Gilead’s radar for sure since Covid and before that but now we have ViiV, Certainly GSK with the inventor of maraviroc at their clinical helm And PFE through the ViiV connection. You throw inJ&J because Of the Rilpivirine Connection and you have the stage for a bidding war..
As you highlighted, I think Gilead is being boxed out. They’re Onc program is Arguably lacking and HCV program is a cure market that is declining. HIV right now is rolling but if you add in and outside agitator with LL that has a cure that’s going to be a big problem for them..
Agree with you on reading the boards and letting our minds share thoughts that lead to promising suggestions.. I prefer to read the boards on Nights like tonight where substance from multiple people leads to creative thought.
Thank you for your postS.
There is a combination of PFE, GSK and ViiV And maybe they have some sort of agreement together or maybe it is just ViiV That is making the move.
But the appointment of Dr. LATA is certainly the first real card we have been dealt that shows us that there is a collaboration going on possibly licensing and partnership, and hopefully the goal of a buyout.
The global component is interesting, but I don’t want to go down the road that MGK2 Going down that says we are going to subvert the FDA by going into another country first. We have gone through hell with the FDA and Dr. Jay has resurrected that relationship and it would be incredibly foolish to not go through the FDA first.. The biggest market in medicine is the United States and that’s where we need to be focused and we have been told that we have a healthy promising relationship with the FDA so let’s keep going down that path
Sure, we can go overseas later and we can begin to build relationships of course but just because GSK is based out of London and has important relationships with the EMA does not mean that they don’t also have equally solid relationships with our FDA.
Doctor LATA is here for a reason and he certainly is in a position to keep a very close eye on the molecule and what CYDY does with it. He is something we have been missing for as long as I have known about this molecule, which is coming up on 11 years..
So what I have talked about tonight with my multiple posts As was pointed out byrodolfo, Is that it seems something is brewing and that something is with big Pharma.
We had MERCK with the Keytrufa Mouse studies at MD Anderson and we have been on Gilead’s radar for sure since Covid and before that but now we have ViiV, Certainly GSK with the inventor of maraviroc at their clinical helm And PFE through the ViiV connection. You throw inJ&J because Of the Rilpivirine Connection and you have the stage for a bidding war..
As you highlighted, I think Gilead is being boxed out. They’re Onc program is Arguably lacking and HCV program is a cure market that is declining. HIV right now is rolling but if you add in and outside agitator with LL that has a cure that’s going to be a big problem for them..
Agree with you on reading the boards and letting our minds share thoughts that lead to promising suggestions.. I prefer to read the boards on Nights like tonight where substance from multiple people leads to creative thought.
Thank you for your postS.
9
